Emergent BioSolutions (EBS) Misses Q4 EPS by 16c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.32 -0.83%
Revenue Growth %: +32.0%
Financial Fact:
Selling, general and administrative: 40.69M
Today's EPS Names:
PLCE, COE, JVA, More
Revenue Growth %: +32.0%
Financial Fact:
Selling, general and administrative: 40.69M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of $1.57, $0.16 worse than the analyst estimate of $1.73. Revenue for the quarter came in at $360.4 million versus the consensus estimate of $357.41 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- Nvidia pitches Vera CPU to Chinese clients with August delivery target
- 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
